Ypsomed Holding AG (XSWX:YPSN)

CHF 330 3.5 (1.07%) Market Cap: 4.50 Bil Enterprise Value: 4.69 Bil PE Ratio: 60.55 PB Ratio: 7.25 GF Score: 88/100

Half Year 2024 Ypsomed Holding AG Earnings Call Transcript
Nov 15, 2023

CHF270 (-1.28%)

Earnings
Full Year 2023 Ypsomed Holding AG Earnings Call Transcript
May 24, 2023

CHF226 (-1.53%)

Earnings
Full Year 2022 Ypsomed Holding AG Earnings Call Transcript
May 25, 2022

CHF139.37 (-1.55%)

Earnings
Half Year 2022 Ypsomed Holding AG Earnings Call Transcript
Nov 04, 2021

CHF164.49 (+5.50%)

Earnings
Full Year 2021 Ypsomed Holding AG Earnings Call Transcript
May 26, 2021

CHF151.33 (+5.56%)

Earnings
Half Year 2021 Ypsomed Holding AG Earnings Call Transcript
Nov 03, 2020

CHF119.63 (-0.33%)

Earnings
Full Year 2020 Ypsomed Holding AG Earnings Call Transcript
May 27, 2020

CHF140.37 (+0.86%)

Earnings
Half Year 2020 Ypsomed Holding AG Earnings Call Transcript
Nov 05, 2019

CHF137.58 (-5.99%)

Earnings
Full Year 2019 Ypsomed Holding AG Earnings Call Transcript
May 23, 2019

CHF127.61 (-7.38%)

Earnings

Full Year 2022 Ypsomed Holding AG Earnings Call Transcript

May 25, 2022 / 01:00PM GMT

Release Date Price: CHF139.37 (-1.55%)

Transcript

Operator

Good day, ladies and gentlemen. Welcome to the financial year 2021/'22 conference call of Ypsomed. (Operator Instructions) I would like to introduce your host for today's conference, Mr. Thomas Kutt, Head Investor Relations. Sir, the floor is yours.

Thomas Kutt

Ypsomed Holding AG - Head of IR

Thank you, Gabrielle. Good day, ladies and gentlemen, and thank you for joining us for our financial year '21/'22 Results Conference Call.

Joining me today are Simon Michel, CEO; and Niklaus Ramseier, our CFO. Our press release, report and presentation discussing our financial performance are also available in the Media and Investors section of our website.

With that, I will turn the call to Simon. Simon, please?

Simon Michel

Ypsomed Holding AG - CEO

Thank you, Thomas. Good morning, good afternoon, everybody. Welcome all from my side to the presentation of our annual figures '21/'22. Ypsomed plays a significant role in the treatment of chronic diseases and develops itself into the space of successful

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.